Lumosa Therapeutics Statistics

Total Valuation

TPEX:6535 has a market cap or net worth of TWD 26.62 billion. The enterprise value is 25.84 billion.

Market Cap	26.62B
Enterprise Value	25.84B

Important Dates

The next estimated earnings date is Wednesday, March 11, 2026.

Earnings Date	Mar 11, 2026
Ex-Dividend Date	n/a

Share Statistics

TPEX:6535 has 168.46 million shares outstanding. The number of shares has increased by 1.61% in one year.

Current Share Class	168.46M
Shares Outstanding	168.46M
Shares Change (YoY)	+1.61%
Shares Change (QoQ)	-0.27%
Owned by Insiders (%)	1.33%
Owned by Institutions (%)	6.67%
Float	89.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	742.85
PB Ratio	17.52
P/TBV Ratio	17.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-75.87
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-71.53

Financial Position

The company has a current ratio of 7.37, with a Debt / Equity ratio of 0.00.

Current Ratio	7.37
Quick Ratio	6.28
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-1,659.15

Financial Efficiency

Return on equity (ROE) is -20.11% and return on invested capital (ROIC) is -12.04%.

Return on Equity (ROE)	-20.11%
Return on Assets (ROA)	-11.02%
Return on Invested Capital (ROIC)	-12.04%
Return on Capital Employed (ROCE)	-21.95%
Weighted Average Cost of Capital (WACC)	4.47%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	43
Asset Turnover	0.02
Inventory Turnover	0.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.09% in the last 52 weeks. The beta is 0.04, so TPEX:6535's price volatility has been lower than the market average.

Beta (5Y)	0.04
52-Week Price Change	-30.09%
50-Day Moving Average	181.67
200-Day Moving Average	192.05
Relative Strength Index (RSI)	32.83
Average Volume (20 Days)	283,179

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6535 had revenue of TWD 35.83 million and -340.54 million in losses. Loss per share was -2.05.

Revenue	35.83M
Gross Profit	21.87M
Operating Income	-333.49M
Pretax Income	-346.62M
Net Income	-340.54M
EBITDA	-322.23M
EBIT	-333.49M
Loss Per Share	-2.05

Full Income Statement

Balance Sheet

The company has 798.34 million in cash and 6.92 million in debt, giving a net cash position of 791.42 million or 4.70 per share.

Cash & Cash Equivalents	798.34M
Total Debt	6.92M
Net Cash	791.42M
Net Cash Per Share	4.70
Equity (Book Value)	1.52B
Book Value Per Share	9.11
Working Capital	835.06M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -360.50 million and capital expenditures -668,000, giving a free cash flow of -361.16 million.

Operating Cash Flow	-360.50M
Capital Expenditures	-668,000
Free Cash Flow	-361.16M
FCF Per Share	-2.14

Full Cash Flow Statement

Margins

Gross Margin	61.04%
Operating Margin	-930.73%
Pretax Margin	-967.37%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TPEX:6535 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.61%
Shareholder Yield	-1.61%
Earnings Yield	-1.28%
FCF Yield	-1.36%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6535 has an Altman Z-Score of 153.5 and a Piotroski F-Score of 1.

Altman Z-Score	153.5
Piotroski F-Score	1